Our study aimed to determine the effects of new-onset neurological symptoms (NNS) on clinically relevant outcomes in hospitalized patients with COVID-19 infection. We conducted a nationwide, comparative, retrospective, cohort study among adult, hospitalized COVID-19 patients involving 37 hospital sites from various regions in the Philippines. We included a total of 10,881 patients with confirmed COVID-19 infection (2008 had NNS while 8873 did not have NNS). The adjusted hazard ratios (aHRs) for mortality among the mild and severe cases were significantly higher by 1.660 (95% CI 1.132–2.435) and by 1.352 (95% CI 1.042–1.752), respectively, in the NNS group compared to those in the non-NNS group. The aHRs for respiratory failure in the NNS group were significantly increased by 1.914 (95% CI 1.346–2.722), by 1.614 (95% CI 1.260–2.068), and by 1.234 (95% CI 1.089–1.398) among the mild, severe, and critical cases, respectively. The aHRs for ICU admission in the NNS group were still significantly higher by 1.973 (95% CI 1.457–2.673) and by 1.831 (95% CI 1.506–2.226) among the mild and severe cases, respectively. Patients who had NNS were not significantly associated with a longer duration of ventilator dependence (adjusted odds ratio (aOR) 0.954, 95% CI 0.772–1.179), longer ICU stay (aOR 0.983, 95% CI 0.772–1.252) and longer hospital admission (aOR 1.045, 95% CI 0.947–1.153). The presence of NNS significantly increases the risk of mortality, respiratory failure and ICU admission among COVID-19 patients. Registration and associated protocol publication: ClinicalTrials.gov website (NCT04386083); Espiritu AI, Sy MCC, Anlacan VMM, Jamora RDG. The Philippine COVID-19 Outcomes: a Retrospective study Of Neurological manifestations and Associated symptoms (The Philippine CORONA study): a protocol study. BMJ Open. 2020;10:e040944.

我们的研究旨在确定新发神经系统症状 (NNS) 对 COVID-19 感染住院患者临床相关结果的影响。我们对来自菲律宾不同地区的 37 个医院地点的成年住院 COVID-19 患者进行了一项全国性的比较性回顾性队列研究。我们总共纳入了 10,881 名确诊 COVID-19 感染的患者（2008 年有 NNS，而 8873 名没有 NNS）。与 NNS 组相比，轻度和重度病例死亡率的调整风险比 (aHR) 分别显着高出 1.660（95% CI 1.132-2.435）和 1.352（95% CI 1.042-1.752）。非 NNS 组。NNS 组呼吸衰竭的 aHR 显着增加了 1.914（95% CI 1.346–2.722）、1.614（95% CI 1.260–2.068）和 1。轻度、重度和危重病例中分别有 234 例（95% CI 1.089–1.398）。在轻度和重度病例中，NNS 组入住 ICU 的 aHR 仍分别显着高出 1.973（95% CI 1.457-2.673）和 1.831（95% CI 1.506-2.226）。患有 NNS 的患者与更长的呼吸机依赖持续时间（调整优势比 (aOR) 0.954, 95% CI 0.772–1.179）、更长的 ICU 停留时间（aOR 0.983, 95% CI 0.772–1.252）和更长的住院时间没有显着相关性（aOR 1.045，95% CI 0.947–1.153）。NNS 的存在显着增加了 COVID-19 患者死亡、呼吸衰竭和入住 ICU 的风险。注册和相关方案发布：ClinicalTrials.gov 网站（NCT04386083）；Espiritu AI, Sy MCC, Anlacan VMM, Jamora RDG。菲律宾 COVID-19 结果：神经系统表现和相关症状的回顾性研究（菲律宾 CORONA 研究）：协议研究。英国医学杂志公开赛。2020;10:e040944。